Terms: = Breast cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Staging
48 results:
1. brca1 methylation in breast duct carcinoma, a practical study in Duhok-Iraq.
Hasan NA; Pity IS
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):34-39. PubMed ID: 38279496
[TBL] [Abstract] [Full Text] [Related]
2. Counselling Framework for Germline
Wong SM; Apostolova C; Eisenberg E; Foulkes WD
Curr Oncol; 2024 Jan; 31(1):350-365. PubMed ID: 38248108
[TBL] [Abstract] [Full Text] [Related]
3. [Application of genetic counseling and preventive surgery in hereditary breast-ovarian cancer syndrome based on a rare family].
Liu SH; Dong L; Li B; Zhao D; Ying JM
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):796-802. PubMed ID: 37805444
[No Abstract] [Full Text] [Related]
4. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
Seban RD; Arnaud E; Loirat D; Cabel L; Cottu P; Djerroudi L; Hescot S; Loap P; Bonneau C; Bidard FC; Huchet V; Jehanno N; Berenbaum A; Champion L; Buvat I
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4024-4035. PubMed ID: 37606858
[TBL] [Abstract] [Full Text] [Related]
5. Acquired Angioedema in Selected Neoplastic Diseases.
Zając M; Bożek A; Kozłowska R; Grzanka A
Medicina (Kaunas); 2023 Mar; 59(4):. PubMed ID: 37109602
[No Abstract] [Full Text] [Related]
6. Management of patients with advanced epithelial ovarian cancer: a European survey.
Jochum F; Angeles MA; Balaya V; Drouin L; Nikolova T; Mathevet P; Lécuru F; Azais H; Betrian S; Bolze PA; Dabi Y; Kerbage Y; Sanson C; Zaccarini F; Guyon F; Akladios C; Hsu A; Bendifallah S; Deluche E; Guani B
Arch Gynecol Obstet; 2023 Aug; 308(2):535-549. PubMed ID: 36737552
[TBL] [Abstract] [Full Text] [Related]
7. Expression of brca1 by immunohistochemistry and its association with ER, PR, Her2neu status in infiltrative ductal carcinoma of breast.
Soman PS; Hemalatha A; Sreeramulu PN
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S706-S711. PubMed ID: 38384043
[TBL] [Abstract] [Full Text] [Related]
8. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation.
Okada K; Uemura K; Okamoto W; Sumiyoshi T; Shintakuya R; Otsuka H; Serikawa M; Ishii Y; Arihiro K; Takahashi S
Clin J Gastroenterol; 2023 Apr; 16(2):283-288. PubMed ID: 36574187
[TBL] [Abstract] [Full Text] [Related]
9. Incidence of Occult breast cancer in Carriers of brca1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?
Wong SM; Ferroum A; Apostolova C; Alhassan B; Prakash I; Basik M; Boileau JF; Meterissian S; Aleynikova O; Wong N; Foulkes WD
Ann Surg Oncol; 2022 Oct; 29(11):6660-6668. PubMed ID: 35616744
[TBL] [Abstract] [Full Text] [Related]
10. Ovarian stimulation for fertility treatments and risk of breast cancer: a matched cohort study.
Machtinger R; Fallach N; Goldstein I; Chodick G; Schiff E; Orvieto R; Mashiach R
Hum Reprod; 2022 Mar; 37(3):577-585. PubMed ID: 34871410
[TBL] [Abstract] [Full Text] [Related]
11. Detection of brca1/2 Mutation and Analysis of Clinicopathological Characteristics in 141 Cases of Ovarian cancer.
Li L; Chen F; Lin A; Wang D; Shi Y; Chen G
Comput Math Methods Med; 2021; 2021():4854282. PubMed ID: 34721658
[TBL] [Abstract] [Full Text] [Related]
12. [Ductal adenocarcinoma of the pancreas: subtypes and molecular pathology].
Schlitter AM; Konukiewitz B; Kasajima A; Reichert M; Klöppel G
Pathologe; 2021 Sep; 42(5):464-471. PubMed ID: 34402977
[TBL] [Abstract] [Full Text] [Related]
13. Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for brca1/2-associated breast cancer: a case report.
Kuji S; Kondo H; Ohara T; Deura I; Tozawa-Ono A; Migita O; Kawamoto H; Tsugawa K; Chosokabe M; Koike J; Maeda I; Suzuki N
Jpn J Clin Oncol; 2021 Mar; 51(3):492-497. PubMed ID: 33377156
[TBL] [Abstract] [Full Text] [Related]
14. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.
Poortmans PM; Weltens C; Fortpied C; Kirkove C; Peignaux-Casasnovas K; Budach V; van der Leij F; Vonk E; Weidner N; Rivera S; van Tienhoven G; Fourquet A; Noel G; Valli M; Guckenberger M; Koiter E; Racadot S; Abdah-Bortnyak R; Van Limbergen EF; Engelen A; De Brouwer P; Struikmans H; Bartelink H;
Lancet Oncol; 2020 Dec; 21(12):1602-1610. PubMed ID: 33152277
[TBL] [Abstract] [Full Text] [Related]
15. Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Keup C; Benyaa K; Hauch S; Sprenger-Haussels M; Tewes M; Mach P; Bittner AK; Kimmig R; Hahn P; Kasimir-Bauer S
Cell Mol Life Sci; 2020 Feb; 77(3):497-509. PubMed ID: 31254045
[TBL] [Abstract] [Full Text] [Related]
16. Outcome and Prognostic Impact of Surgical staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
Van der Hoeven NMA; Van Wijk K; Bonfrer SE; Beltman JJ; Louwe LA; De Kroon CD; Van Asperen CJ; Gaarenstroom KN
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):463-471. PubMed ID: 29691126
[TBL] [Abstract] [Full Text] [Related]
17. Changes in classification of genetic variants in brca1 and BRCA2.
Kast K; Wimberger P; Arnold N
Arch Gynecol Obstet; 2018 Feb; 297(2):279-280. PubMed ID: 29302806
[TBL] [Abstract] [Full Text] [Related]
18. DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.
De Gregoriis G; Ramos JA; Fernandes PV; Vignal GM; Brianese RC; Carraro DM; Monteiro AN; Struchiner CJ; Suarez-Kurtz G; Vianna-Jorge R; de Carvalho MA
Cancer Biol Ther; 2017 Jun; 18(6):439-449. PubMed ID: 28475402
[TBL] [Abstract] [Full Text] [Related]
19. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline brca1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract] [Full Text] [Related]
20. Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status.
Jiang HS; Kuang XY; Sun WL; Xu Y; Zheng YZ; Liu YR; Lang GT; Qiao F; Hu X; Shao ZM
Oncotarget; 2016 Jul; 7(27):41285-41293. PubMed ID: 27285752
[TBL] [Abstract] [Full Text] [Related]
[Next]
